A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Jan 2021 Results of systemic review of 6 trials (Reck et al 2013, Reck et al 2016, IMpower 133, EA5161, KEYNOTE-604, CASPIAN) assessing difference in both efficacy and safety profiles among different Immuno-Oncology (IO) agents in combination with platinum-based CT in ES-SCLC patients according to different ICIs subtypes, presented at the 2020 World Conference on Lung Cancer.
- 02 Aug 2012 Results in the cohort of patients with extensive SCLC published in the Annals of Oncology.
- 13 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.